Evogene Ltd Ord (EVGN) Stock Price, Quote & News

Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commerci...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 931 1900

Fax: 972 8 946 6724

Website: www.evogene.com

Address:

13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel

Green_backs Aug. 18 at 5:36 PM

$EVGN surprised this hasn’t moved more

0 · Reply

EarningsInsider Aug. 18 at 2:16 PM

https://www.marketbeat.com/earnings/reports/2026-8-18-evogene-ltd-stock/ $EVGN Evogene Earnings Transcript

0 · Reply

Green_backs Aug. 18 at 1:02 PM

$EVGN bullish

0 · Reply

KAMIKAZ3TIGER Aug. 18 at 1:01 PM

$EVGN nice earnings beat!! Wow! Can we rally to $5+ now?

0 · Reply

StocktwitsEarnings Aug. 18 at 12:58 PM

$EVGN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.14 up 72.00% YoY • Reported revenue of $0.35M down -60.75% YoY • Evogene expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024, with further reductions targeted.

0 · Reply

gekkooo Aug. 18 at 12:12 PM

$EVGN dilute shareholders is coming soon! Ofer Haviv is a world class in diluting shareholders and reverse splitt! big trash company !It has no place on the stock exchange. ONLY YOU SHAREHOLDERS FEED THE MANAGEMENT!

0 · Reply

gekkooo Aug. 18 at 12:09 PM

$EVGN target $ 0

0 · Reply

omenkes Aug. 17 at 2:52 PM

$EVGN first time that there is a chance to free the assets from the management (unless they come with a viable plan to monetize assets and stop the insane dilution).

0 · Reply

omenkes Aug. 17 at 2:49 PM

$EVGN somebody is doing a dump. have seen it so many times in the past. if the value is there, shareholders will try to release it and not just get diluted again.

0 · Reply

omenkes Aug. 17 at 1:39 PM

$EVGN last question: can current management have the company generating funds?

0 · Reply

Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35%

2026-08-18T16:56:42.000Z - 20 hours ago

Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress

Aug 18, 2026, 9:00 AM EDT - 1 day ago

Evogene Earnings Call Transcript: Q2 2026

Aug 18, 2026, 9:00 AM EDT - 1 day ago

Evogene Earnings release: Q2 2026

Tue, 18 Aug 2026 08:04:00 -0400 - 1 day ago

Evogene Reports Second Quarter and First Half 2026 Financial Results

2026-08-17T13:17:25.000Z - 2 days ago

Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside

Fri, 14 Aug 2026 07:00:00 -0400 - 5 days ago

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Thu, 30 Jul 2026 07:00:00 -0400 - 20 days ago

Evogene Schedules Second Quarter 2026 Financial Results Release

2026-07-22T13:31:58.000Z - 4 weeks ago

Evogene (EVGN) Partners with ELEO for PCSK9 Inhibitor Development

2026-07-22T12:06:12.000Z - 4 weeks ago

Evogene and ELEO announce scientific collaboration

Wed, 22 Jul 2026 08:00:00 -0400 - 4 weeks ago

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Wed, 15 Jul 2026 07:30:00 -0400 - 5 weeks ago

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

2026-07-08T12:28:10.000Z - 6 weeks ago

Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation

2026-07-08T11:11:22.000Z - 6 weeks ago

Evogene, BCDD announces strategic joint initiative

Wed, 08 Jul 2026 07:00:00 -0400 - 6 weeks ago

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

2026-06-24T13:29:04.000Z - 2 months ago

Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud

2026-06-24T12:10:55.000Z - 2 months ago

Evogene achieves integration of agentic systems with ChemPass AI platform

GOOG GOOGL

Wed, 24 Jun 2026 08:00:00 -0400 - 2 months ago

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Evogene Slides: Company presentation

Tue, 09 Jun 2026 07:00:00 -0400 - 2 months ago

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

2026-06-02T12:34:46.000Z - 2 months ago

Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results

2026-06-02T11:06:21.000Z - 2 months ago

Evogene says Phase 1 clinical study of BMC128 met primary endpoint

Tue, 02 Jun 2026 07:00:00 -0400 - 2 months ago

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

2026-05-26T19:10:13.000Z - 3 months ago

Evogene price target lowered to $2.15 from $2.25 at Alliance Global

2026-05-20T14:42:55.000Z - 3 months ago

Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected

May 20, 2026, 9:00 AM EDT - 3 months ago

Evogene Earnings Call Transcript: Q1 2026

May 20, 2026, 9:00 AM EDT - 3 months ago

Evogene Earnings release: Q1 2026

2026-05-20T12:29:49.000Z - 3 months ago

Evogene (EVGN) Reports Decrease in Q1 Revenue Amid Strategic Transformation

2026-05-20T11:11:26.000Z - 3 months ago

Evogene reporta Q1 cont. ops. EPS (60c) vs. (26c) last year

Wed, 20 May 2026 07:00:00 -0400 - 3 months ago

Evogene Reports First Quarter 2026 Financial Results

Tue, 12 May 2026 08:00:00 -0400 - 3 months ago

Evogene to Present at the 24th Schrödinger European User Group Meeting

Thu, 07 May 2026 08:00:00 -0400 - 3 months ago

Evogene Schedules First Quarter 2026 Financial Results Release

2026-04-13T14:21:10.000Z - 4 months ago

Evogene price target raised to $2.25 from $1.75 at Alliance Global

2026-04-02T21:27:08.000Z - 4 months ago

Evogene (EVGN) Faces Nasdaq Compliance Challenge Over Bid Price

2026-04-02T20:05:46.000Z - 4 months ago

Evogene receives Nasdaq minimum bid price notification

Thu, 02 Apr 2026 16:01:00 -0400 - 4 months ago

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Tue, 31 Mar 2026 08:00:00 -0400 - 5 months ago

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

2026-03-26T20:35:48.000Z - 5 months ago

Evogene files to sell 5.08M ordinary shares for holders

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Evogene Registration statement: Registration filing

2026-03-13T15:40:44.000Z - 5 months ago

Evogene price target lowered to $1.75 from $2.50 at Alliance Global

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Evogene Slides: Corporate presentation

Mon, 09 Mar 2026 09:00:00 -0400 - 5 months ago

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Mar 5, 2026, 9:00 AM EST - 5 months ago

Evogene Earnings Call Transcript: Q4 2025

Mar 5, 2026, 9:00 AM EST - 5 months ago

Evogene Annual report: Q4 2025

Mar 5, 2026, 9:00 AM EST - 5 months ago

Evogene Quarterly report: Q4 2025

2026-03-05T12:41:07.000Z - 5 months ago

Evogene (EVGN) Focuses on Key Markets Following Strategic Shift

2026-03-05T12:10:35.000Z - 5 months ago

Evogene Earnings Review: Q4 Summary

2026-03-05T12:09:46.000Z - 5 months ago

Evogene reports Q4 cont ops EPS (61c) vs. 17c last year

Thu, 05 Mar 2026 07:00:00 -0500 - 5 months ago

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-04T19:01:57.000Z - 5 months ago

An Overview of Evogene's Earnings

Wed, 25 Feb 2026 08:00:00 -0500 - 6 months ago

Evogene Releases CEO Letter to Shareholders

Thu, 19 Feb 2026 08:00:00 -0500 - 6 months ago

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

2026-02-17T13:33:51.000Z - 6 months ago

Evogene (EVGN) Partners with QUT to Combat Lung Cancer Drug Resistance

2026-02-17T13:10:12.000Z - 6 months ago

Evogene collaborates with Queensland University in AI-driven cancer therapeutics

Tue, 17 Feb 2026 08:00:00 -0500 - 6 months ago

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Wed, 11 Feb 2026 08:00:00 -0500 - 6 months ago

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Tue, 10 Feb 2026 13:20:00 -0500 - 6 months ago

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

2026-02-10T13:29:55.000Z - 6 months ago

Evogene (EVGN) Expands Collaboration with Google Cloud to Boost AI Capabilities

2026-02-10T13:16:48.000Z - 6 months ago

Evogene expands collaboration with Google Cloud for AI agents into ChemPass AI

GOOG GOOGL

Tue, 10 Feb 2026 08:00:00 -0500 - 6 months ago

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Feb 9, 2026, 8:00 AM EST - 6 months ago

Evogene Appoints Prof. John Irwin and Prof.

2026-02-05T11:00:14.000Z - 6 months ago

Evogene, Shanghai Lishan Biopharmaceuticals enter BMC128 licensing agreement

Feb 4, 2026, 10:00 PM EST - 6 months ago

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

2026-02-04T13:05:13.000Z - 7 months ago

Biomica and Lishan Biotech sign licensing agreement for BMC128

2026-01-07T12:15:13.000Z - 8 months ago

Evogene, Unravel Biosciences announce scientific collaboration

Jan 7, 2026, 7:00 AM EST - 8 months ago

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

2025-12-30T12:10:49.000Z - 8 months ago

Evogene appoints Nissan as VP of Business Development

Dec 30, 2025, 7:00 AM EST - 8 months ago

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Nov 20, 2025, 9:00 AM EST - 9 months ago

Evogene Earnings Call Transcript: Q3 2025

Nov 20, 2025, 9:00 AM EST - 9 months ago

Evogene Quarterly report: Q3 2025

Nov 20, 2025, 7:00 AM EST - 9 months ago

Evogene Reports Third Quarter 2025 Financial Results

2025-11-11T12:11:04.000Z - 10 months ago

Evogene’s Casterra and Fantini announce strategic collaboration

Nov 11, 2025, 7:00 AM EST - 10 months ago

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Nov 6, 2025, 9:00 AM EST - 10 months ago

Evogene Schedules Third Quarter 2025 Financial Results Release

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Aug 19, 2025, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q2 2025

Aug 19, 2025, 9:00 AM EDT - 1 year ago

Evogene Quarterly report: Q2 2025

Aug 19, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules Second Quarter 2025 Financial Results Release

Jul 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

ICL

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Jun 1, 2025, 6:00 AM EDT - 1 year ago

Evogene Slides: Company Presentation

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Earnings Call Transcript: Q1 2025

May 21, 2025, 9:00 AM EDT - 1 year ago

Evogene Quarterly report: Q1 2025

May 21, 2025, 7:00 AM EDT - 1 year ago

Evogene Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

Evogene Schedules First Quarter 2025 Financial Results Release

Apr 21, 2025, 7:00 AM EDT - 1 year ago

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Annual report: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Earnings release: Q4 2024

Mar 6, 2025, 9:00 AM EST - 1 year ago

Evogene Slides: Q4 2024

Mar 6, 2025, 7:15 AM EST - 1 year ago

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 6, 2025, 7:00 AM EST - 1 year ago

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Feb 13, 2025, 8:00 AM EST - 1 year ago

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Dec 19, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Company Presentation

Nov 28, 2024, 7:00 AM EST - 1 year ago

Evogene Slides: Corporate Presentation

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Earnings Call Transcript: Q3 2024

Nov 21, 2024, 9:00 AM EST - 1 year ago

Evogene Quarterly report: Q3 2024

Nov 21, 2024, 7:30 AM EST - 1 year ago

Evogene Reports Third Quarter 2024 Financial Results

Nov 19, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Nov 7, 2024, 7:00 AM EST - 1 year ago

Evogene Schedules Third Quarter 2024 Financial Results Release

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Oct 8, 2024, 7:00 AM EDT - 2 years ago

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Sep 30, 2024, 7:00 AM EDT - 2 years ago

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Green_backs Aug. 18 at 5:36 PM

$EVGN surprised this hasn’t moved more

0 · Reply

EarningsInsider Aug. 18 at 2:16 PM

https://www.marketbeat.com/earnings/reports/2026-8-18-evogene-ltd-stock/ $EVGN Evogene Earnings Transcript

0 · Reply

Green_backs Aug. 18 at 1:02 PM

$EVGN bullish

0 · Reply

KAMIKAZ3TIGER Aug. 18 at 1:01 PM

$EVGN nice earnings beat!! Wow! Can we rally to $5+ now?

0 · Reply

StocktwitsEarnings Aug. 18 at 12:58 PM

0 · Reply

gekkooo Aug. 18 at 12:12 PM

0 · Reply

gekkooo Aug. 18 at 12:09 PM

$EVGN target $ 0

0 · Reply

omenkes Aug. 17 at 2:52 PM

$EVGN first time that there is a chance to free the assets from the management (unless they come with a viable plan to monetize assets and stop the insane dilution).

0 · Reply

omenkes Aug. 17 at 2:49 PM

$EVGN somebody is doing a dump. have seen it so many times in the past. if the value is there, shareholders will try to release it and not just get diluted again.

0 · Reply

omenkes Aug. 17 at 1:39 PM

$EVGN last question: can current management have the company generating funds?

0 · Reply

omenkes Aug. 17 at 1:29 PM

$EVGN Casterra also was based on generator ai. the issue was that they were solving a problem that is not yet big enough in Africa. in Brasil there are better conditions and better opportunity for Castor. time will tell. ChemPass AI - like the first two engines, this one has an ag side (agplenus) and a human side (chempass ai or evogene - no specific name yet). it is interesting the the partnerships of chempass so far are in deseases that were investigated before from the microboost side (biomica) and my guess is that the results of the probiotics gave a good starting point to develop new molecules for these deseases. to be continued.

0 · Reply

omenkes Aug. 17 at 1:11 PM

$EVGN I started a while ago to explain about Agplenus, but at this point the issue about Evogene is different and the ceo + chairman of the board need to come clean about things: 1. the assets are three engines: Microboost AI - Verb Biotics is using it to create a line of probiotics that actually deal with a single strain with a health issue. first one on the market is LP815. Verb have an alliance with Opella for that (50% owned by Sanofi and sells $10B of products). Lavie Bio worked on that engine and so was Biomica. Biomica has their BMC128 (new name to it by Lishan is LS-LBP-002) on its way to phase 2 for RCC. Generator AI - Finally foods used it for creation of a potato which has 10% of the four casein (milk) proteins. now they are in front of getting regulatory agreement and then industrial production (which was already demonstrated). 40% of finally foods is owned by Evogene and BCB group and Straus group own much of the rest. these are big dairy players. to be continued.

0 · Reply

ikerrr Aug. 14 at 3:37 PM

$EVGN NEWS- CHAIRMRN NIR NIMRODI TO ADDRESS DISSIDENT SHAREHOLDERS DURING CONFERENCE CALL Well Mr. Nimrodi shareholders don't believe anything you say. We're voting your ass out because you've produced nothing but shitty results and we're voting for PURE CAPITAL! See ya Numb Nuts Nimrodi you're a loser! Vote PURE CAPITAL

0 · Reply

ikerrr Aug. 14 at 2:42 PM

$EVGN Vote Pure Capital!

0 · Reply

ikerrr Aug. 14 at 2:40 PM

$EVGN Vote Pure Capital!

0 · Reply

ikerrr Aug. 14 at 2:35 PM

$EVGN Vote Pure Capital!

0 · Reply

ikerrr Aug. 14 at 2:33 PM

$EVGN Nickel, Yea and that same billionaire financier is part of the problem. Sitting on the board, taking big perks while the stock has tanked by 99.32% since inception and will sell his shares immediately after the proxy vote anyway. Then after he sells his shares, he'll vote in favor of a 10 to 1 reverse split, vote for more shares issued and current shareholders will be screwed to the max while he returns to the board and continues receiving big compensation. Whereas activist investor Pure Capital will stop this BS and sell off this company for the current shareholders who I believe are in at a very low price due to the current boards ineptness.(I'm in for 100,000 shares at about a dollar per share, but have watched this valuable company do nothing but tank) So do you want to see a 15 million share company become a 150 share company while your shares decrease 90% or do you want to see Pure Capital sell this company for 3 or 4 dollars and current shareholders finally win

0 · Reply

Nickel_P_Dimes Aug. 13 at 8:43 PM

$EVGN A billionaire Israeli financier who has been on this board for 21 years just put nearly $700K into a sub-dollar stock five days before earnings, while the company faces a Nasdaq compliance deadline, has a reverse split vote coming, and just stacked three new AI pharma collaborations. He's either positioning for a partnership announcement on the earnings call, a reverse split that will compress the float dramatically, or both. Either way, he's telling you with his wallet that he doesn't think this company is going to zero.

0 · Reply

ikerrr Aug. 11 at 8:48 PM

$EVGN be sure you vote for the Pure Capital board duing the proxy vote`if you own EVGN shares as of today August 11 or we're screwed

1 · Reply

topstockalerts Aug. 10 at 11:01 PM

After Hours Top Gainers PT2 $GENK $MTEN $EVGN $FRMI $MGIH

0 · Reply

Luckyizme Aug. 10 at 4:06 PM

$EVGN Wow! They scammed it all back. P&D almost always when insider buys.

0 · Reply

ajmrtxl Aug. 10 at 4:05 PM

$EVGN 's latest data on SqueezeFinder

0 · Reply

Market Cap	4.88M
Revenue (ttm)	3.85M
Net Income (ttm)	-8.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-220.52%
Debt to Equity Ratio	0.00

Volume	151,100
Avg Vol	1,794,182
Day's Range	N/A - N/A
Shares Out	8.72M
Stochastic %K	16%
Beta	1.40
Analysts	Strong Buy
Price Target	$2.15